TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: In (M1), the glycolipid and/or glycoprotein are of a cytoplasmic membrane surface. The cell in which the glycolipid and/or glycoprotein are present, is a skin keratinocyte, cell of skin tissue, HEK293 cell, a neuron or an astrocyte.    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Sugar Chain: The binding of sugar chain with glycolipid and/or glycoprotein is by cross-linking of the sugar chain by hydrogen bond. The ginsenoside Rb1-like substance has sugar chain selected from glucose, galactose, N-acetyl glucosamine, fucose, sialic acid, xylose, mannose, talose, fructose, allose, altrose, gulose, idose, ribose, arabinose, N-acetylgalactosamine, rhamnose, 2-deoxyglucose, an oligosaccharide or rare saccharide.Preferred Composition: (I) is a glycoside compound having dihydroxy-, trihydroxy- or tetrahydroxychromene, as a basic structure and their salts or compositions. (I) is a glycoside compound of formula (I'), their salts or their compositions.R1-R3 = 1-10C acyl, alkyl, aralkyl, aryl or halogen; andRa-Rc = H, 1-10C alkyl, aralkyl, acyl, alkynyl or hydroxyl;where R1,R2 and R3 express an unsubstituted 1-10C acyl group, Ra, Rb and Rc independently express a hydrogen atom. ACTIVITY - Vulnerary; Cytostatic; Neuroprotective; Cerebroprotective; Vasodilator; Cytoprotective; Dermatological; Growth-Regulant.    Burn treatment effect of eucryphin present in the ginsenoside Rb1 substance was evaluated in mouse. A skin external preparation (Propeto) containing 0.005 or 0.05 %, by weight of eucryphin was prepared by adding eucryphin to ophthalmic white vaseline. A thermal-burn lesion (skin whole-layer defect lesion) was formed on the back region of a BALB/C mouse. The prepared propeto was administered externally to the thermal burn region at single dose for 17 days. The wound area of thermal burn region was measured every 2-3 days. A mouse which received the propeto without the eucryphin was included as control in the test. The result showed that the enlargement of wound region by a thermal burn was restricted by the use of propeto containing eucryphin which promoted regeneration of skin tissue.    MECHANISM OF ACTION - None given.    ADMINISTRATION - The ginsenoside Rb1-like substance is administered intravenously (claimed). The ginsenoside Rb1-like substance is also administered parenterally, orally, intranasally, intramuscularly, intracutaneously, percutaneously or as an ophthalmic ointment, eye-drop, ear-drop, or by inhalation. The dosage ranges from 100 microg/ml or less, preferably 10 ng/ml or less.    SPECIFIC COMPOUNDS - (I) is specifically 3,5,7-trihydroxychromen-4-one-3-O-L-rhamnoside (eucryphin) of formula (A).    EXAMPLE - No relevant example is given.